Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Invest New Drugs. 2018 Aug 3;37(2):364–374. doi: 10.1007/s10637-018-0647-0

Fig. 2.

Fig. 2

In vitro activity of Apra S10 in PC cells and tumor associated stromal (TAS-G13) cells. Effects on (a) RTKs (24 h) and (b) VEGF-A secretion (12 h) in PANC-1 and EC46 cells. (c) Effects of on secretion of 41 cytokines/ growth factors in primary cancer EC68 cells (top), tumor associated stromal TAS-G13 cells (bottom). Several affected factors are displayed in (d) for PC and (e) for stromal cells (average of triplicates).